A carregar...
Rosuvastatin pharmacokinetics in Asian and White subjects wild-type for both OATP1B1 and BCRP under control and inhibited conditions
The FDA recommends rosuvastatin dosage reductions in Asian patients because pharmacokinetic studies have demonstrated an approximate two-fold increase in median exposure to rosuvastatin in Asian subjects when compared to Caucasian controls. Yet, no explanation for this ethnic difference has been con...
Na minha lista:
| Publicado no: | J Pharm Sci |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5675025/ https://ncbi.nlm.nih.gov/pubmed/28385543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2017.03.027 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|